1/2期DREAMM-6试验A组结果：复发/难治性多发性骨髓瘤患者使用贝兰他单抗莫福汀联合来那度胺及地塞米松治疗。
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
作者信息
Popat Rakesh, Augustson Bradley, Gironella Mercedes, Lee Cindy, Cannell Paul, Patel Nashita, Kasinathan Ravi S, Rogers Rachel, Shaikh Mehreen, Curry Amy, Carreño Fernando, Roy-Ghanta Sumita, Opalinska Joanna, Quach Hang
机构信息
NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, WA, Australia.
出版信息
Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y.
Abstract
[Image: see text]
摘要
[图像：见正文]
Zotero 插件